First Time Loading...

Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 15.43 USD 3.14% Market Closed
Updated: Apr 28, 2024

Denali Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Denali Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Denali Therapeutics Inc
NASDAQ:DNLI
Revenue
$330.5m
CAGR 3-Years
-1%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.1B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Denali Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
Denali Therapeutics Inc

Not Available

Breakdown by Segments
Denali Therapeutics Inc

Total Revenue: 330.5m USD
100%
Atv:abeta Program License: 288.9m USD
87.4%
Cns Program License: 25m USD
7.6%
Ptv:pgrn Collaboration Agreement: 10m USD
3%
Option Research Services: 1.6m USD
0.5%
Show More
Show Less

See Also

What is Denali Therapeutics Inc's Revenue?
Revenue
330.5m USD

Based on the financial report for Dec 31, 2023, Denali Therapeutics Inc's Revenue amounts to 330.5m USD.

What is Denali Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
21%

Over the last year, the Revenue growth was 205%. The average annual Revenue growth rates for Denali Therapeutics Inc have been -1% over the past three years , 21% over the past five years .